Dr. Abdelnaser Elkhalili, MD
What this data tells you about Dr. Elkhalili
Dr. Abdelnaser Elkhalili is a rheumatology in Webster, TX, with 20 years in practice. Based on federal Medicare data, Dr. Elkhalili performed 145,295 Medicare services across 2,117 unique beneficiaries.
Between the years covered by Open Payments, Dr. Elkhalili received a total of $22,484 from 61 pharmaceutical and/or device companies across 1289 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in rheumatology. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Elkhalili is Very High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
Medicare Practice Summary
Medicare Utilization ↗Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Certolizumab injection (Cimzia) | 55,202 | $4 | $15 |
| Abatacept infusion (Orencia) | 55,060 | $34 | $130 |
| Romosozumab injection (Evenity) for osteoporosis | 16,805 | $8 | $30 |
| Denosumab injection (Prolia/Xgeva) | 5,529 | $18 | $68 |
| Infliximab infusion (Remicade) | 3,611 | $26 | $140 |
| Hyaluronan or derivative, hymovis, for intra-articular injection, 1 mg | 2,304 | $13 | $50 |
| Office visit, established patient (30-39 min) | 1,562 | $95 | $386 |
| Administration of chemotherapy into vein, 1 hour or less | 979 | $102 | $394 |
| Steroid injection (triamcinolone) | 954 | $1 | $3 |
| Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | 549 | $57 | $219 |
| Office visit, established patient, complex (40-54 min) | 497 | $126 | $541 |
| Injection, zoledronic acid, 1 mg | 446 | $7 | $33 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 256 | $51 | $193 |
| Office visit, established patient (20-29 min) | 252 | $69 | $272 |
| Joint injection, major joint | 241 | $59 | $266 |
| Injection, ketorolac tromethamine, per 15 mg | 200 | $0 | $2 |
| Office visit, established patient (10-19 min) | 162 | $43 | $171 |
| Administration of chemotherapy into vein, each additional hour | 154 | $23 | $85 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 128 | $23 | $87 |
| New patient office visit (45-59 min) | 70 | $121 | $503 |
| Drug injection, under skin or into muscle | 61 | $10 | $43 |
| Injection, diphenhydramine hcl, up to 50 mg | 57 | $1 | $3 |
| Injection, methylprednisolone sodium succinate, up to 125 mg | 56 | $4 | $18 |
| Injection, methylprednisolone sodium succinate, up to 40 mg | 48 | $3 | $12 |
| Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | 28 | $1 | $6 |
| Aspiration and/or injection of fluid from small joint | 19 | $44 | $186 |
| Shoulder X-ray, 2+ views | 19 | $28 | $105 |
| X-ray of both knees while standing | 18 | $31 | $121 |
| New patient office visit, complex (60-74 min) | 15 | $142 | $664 |
| X-ray of both hips, 2 views | 13 | $31 | $125 |
Industry Payment Transparency
Open Payments through 2024 ↗Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
Payments by company (2024)
Associated products mentioned in payments ›
Most payments (100%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.
Geographic Context
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This measures how much public data is available about a provider — not how good they are. How we calculate this →
Summary
Dr. Elkhalili is a mixed practice specialist, with above-average Medicare volume (top 9% in TX), and high industry engagement (low-engagement, top 17%), with 20 years of practice experience.
This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →
Frequently Asked Questions
Is Dr. Elkhalili experienced with certolizumab injection (cimzia)?
Does Dr. Elkhalili receive payments from pharmaceutical companies?
How do Dr. Elkhalili's costs compare to other rheumatologys in Webster?
What does Data Coverage mean?
Is this data up to date?
Explore related providers
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology